血小板因子4有效地逆转大鼠的肝素抗凝作用,而没有肝素-原胺复合物的不良影响
J J Cook1, S Niewiarowski, Z Yan
1Department of Physiology, Temple University School of Medicine, Philadelphia, PA 19140.
Circulation
|March 1, 1992
概括
血小板因子4 (PF4) 有效地逆转肝素抗凝作用在大鼠中,没有胺硫酸盐 (PS) 的不良影响. 再组合PF4 (rPF4) 显示出作为PS用于医疗程序的更安全替代品的希望.
科学领域:
- 生物医学研究的研究.
- 药理学 药理学 是一个学科.
- 血液学 血液学 血液学
背景情况:
- 胺硫酸盐 (PS) 逆转肝素抗凝剂会导致白血病和低血压等不良影响.
- 对于患者的安全来说,研究用于乙氨酸中和PS的替代品至关重要.
研究的目的:
- 为了比较本源血小板因子4 (PF4) 和复合PF4 (rPF4) 与PS的疗效和安全性,在体内逆转氨酸抗凝作用.
- 评估PF4和rPF4作为PS更安全的替代品的潜力.
主要方法:
- 用一个大鼠模型来评估PS,PF4和rPF4对肝素的中和.
- 测量的关键参数包括激活的部分血栓形成时间,血小板和白细胞计数,补充位,平均动脉压和肺组织学.
主要成果:
- 所有的药物 (PS,PF4,rPF4) 都有效地逆转了肝素的抗凝活性.
- 脊髓灰质炎导致血小板数量,白细胞数量,补体位数和平均动脉压的显著下降,以及肺和出血.
- PF4和rPF4没有诱导这些不良反应,观察到正常的肺组织学.
结论:
- 在大鼠中,PF4有效地逆转了氨酸抗凝作用,而没有与PS相关的不良影响.
- 重组PF4 (rPF4) 在需要肝素逆转的临床环境中提供了潜在的更安全的PS替代品.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Formation of the Platelet Plug
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
Clot Retraction and Fibrinolysis
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...


